跳至主要内容
临床试验/NCT05881187
NCT05881187尚未招募不适用

Analysis of the Outcomes of Photoactivated Chromophore for Keratitis Cross _linking for Treatment of Infectious Keratitis

Sohag University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年6月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
入组人数
60
试验地点
1
主要终点
corneal THICKNESS

研究概览

简要总结

The primary aim of this study is to investigate the efficiency of PACK_ CXL in treatment of infectious keratitis and analyze postoperative outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • are age ≥18 years, fungal, bacterial or mixed infectious keratitis, ulcer ≤ 4 mm in diameter and showing a maximum depth of 350 μm (as assessed by either optical coherence tomography (OCT))

排除标准

  • age ≤18 years, viral infectious keratitis, non-infectiouskeratitis, melting corneal ulcers with impending perforation, corneal thickness < 400 μm (including the corneal epithelium) and systemic diseases or systemic surgery, single-eyed and immunosuppressed patients.

研究组 & 干预措施

groupA (control group)

Active Comparator

will include 20 eyes of 20 patients with infectious keratitis who will receive antimicrobial therapy.

干预措施: Antibotice.g vigamox ED Antifungal e.g Dflucan (Drug)

group B

Active Comparator

will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated cross-linking Protocol-1 (9 mW/cm2 for 10 minutes to achieve 5.4 J/cm2) followed by antimicrobial therapy

干预措施: Riboflavin (Drug)

group B

Active Comparator

will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated cross-linking Protocol-1 (9 mW/cm2 for 10 minutes to achieve 5.4 J/cm2) followed by antimicrobial therapy

干预措施: Antibotice.g vigamox ED Antifungal e.g Dflucan (Drug)

group B

Active Comparator

will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated cross-linking Protocol-1 (9 mW/cm2 for 10 minutes to achieve 5.4 J/cm2) followed by antimicrobial therapy

干预措施: pack cross linking (Device)

group C

Active Comparator

will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated crosslinking Protocol-2 (18 mW/cm2 for 7 minutes to achieve 7.2 J/cm2) followed by antimicrobial therapy

干预措施: Riboflavin (Drug)

group C

Active Comparator

will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated crosslinking Protocol-2 (18 mW/cm2 for 7 minutes to achieve 7.2 J/cm2) followed by antimicrobial therapy

干预措施: Antibotice.g vigamox ED Antifungal e.g Dflucan (Drug)

group C

Active Comparator

will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated crosslinking Protocol-2 (18 mW/cm2 for 7 minutes to achieve 7.2 J/cm2) followed by antimicrobial therapy

干预措施: pack cross linking (Device)

结局指标

主要结局

corneal THICKNESS

时间窗: within 60 days

decrease corneal THICKNESS USING ANTERIOR SEGMENT OPTICAL COHERENT TOPOGRAPHY

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mariam Abdelmawgoud Mohamed

assistant lecteurer opthalmology department sohag univerisity hospital

Sohag University

研究点 (1)

Loading locations...

相似试验